Details for Patent: 10,959,994
✉ Email this page to a colleague
Which drugs does patent 10,959,994 protect, and when does it expire?
Patent 10,959,994 protects REZLIDHIA and is included in one NDA.
This patent has seventeen patent family members in fourteen countries.
Summary for Patent: 10,959,994
Title: | Solid forms of ((S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile |
Abstract: | The present disclosure reports solid forms of ((S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile. |
Inventor(s): | Luke George P., Sheth Pratik |
Assignee: | FORMA Therapeutics, Inc. |
Application Number: | US16693642 |
Patent Claim Types: see list of patent claims |
Drugs Protected by US Patent 10,959,994
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Rigel Pharms Inc | REZLIDHIA | olutasidenib | CAPSULE;ORAL | 215814-001 | Dec 1, 2022 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 10,959,994
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Denmark | 3720442 | ⤷ Sign Up | |||
European Patent Office | 3720442 | ⤷ Sign Up | |||
European Patent Office | 4215197 | ⤷ Sign Up | |||
Spain | 2941079 | ⤷ Sign Up | |||
Finland | 3720442 | ⤷ Sign Up | |||
Croatia | P20230168 | ⤷ Sign Up | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |